Evidence map›Paper›PMID 38533515›Full record

ArticleFrontiers in immunology2024

TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes.

Prerak Trivedi, Gaurang Jhala, David J De George, Chris Chiu, Claudia Selck, Tingting Ge, Tara Catterall, Lorraine Elkerbout, Louis Boon, Nicole Joller and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Prerak TrivediImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Gaurang JhalaImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
David J De GeorgeImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Chris ChiuImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Claudia SelckImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Tingting GeImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Tara CatterallImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Lorraine ElkerboutImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Louis BoonJJP Biologics, Warsaw, Poland.
Nicole JollerDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Thomas W KayImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Helen E ThomasImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
Balasubramanian KrishnamurthyImmunology and Diabetes Unit, St Vincent's Institute, Fitzroy, VIC, Australia.
St Vincents Institute of Medical Research · AUSt Vincent's Hospital · AUUniversity of Melbourne · AUUniversity of Zurich · CH

Funding

Medical Research Council
6 · The paper itself

Abstract

Introduction: Chronic activation of self-reactive T cells with beta cell antigens results in the upregulation of immune checkpoint molecules that keep self-reactive T cells under control and delay beta cell destruction in autoimmune diabetes. Inhibiting PD1/PD-L1 signaling results in autoimmune diabetes in mice and humans with pre-existing autoimmunity against beta cells. However, it is not known if other immune checkpoint molecules, such as TIGIT, can also negatively regulate self-reactive T cells. TIGIT negatively regulates the CD226 costimulatory pathway, T-cell receptor (TCR) signaling, and hence T-cell function. Methods: The phenotype and function of TIGIT expressing islet infiltrating T cells was studied in non-obese diabetic (NOD) mice using flow cytometry and single cell RNA sequencing. To determine if TIGIT restrains self-reactive T cells, we used a TIGIT blocking antibody alone or in combination with anti-PDL1 antibody. Results: We show that TIGIT is highly expressed on activated islet infiltrating T cells in NOD mice. We identified a subset of stem-like memory CD8+ T cells expressing multiple immune checkpoints including TIGIT, PD1 and the transcription factor EOMES, which is linked to dysfunctional CD8+ T cells. A known ligand for TIGIT, CD155 was expressed on beta cells and islet infiltrating dendritic cells. However, despite TIGIT and its ligand being expressed, islet infiltrating PD1+TIGIT+CD8+ T cells were functional. Inhibiting TIGIT in NOD mice did not result in exacerbated autoimmune diabetes while inhibiting PD1-PDL1 resulted in rapid autoimmune diabetes, indicating that TIGIT does not restrain islet infiltrating T cells in autoimmune diabetes to the same degree as PD1. Partial inhibition of PD1-PDL1 in combination with TIGIT inhibition resulted in rapid diabetes in NOD mice. Discussion: These results suggest that TIGIT and PD1 act in synergy as immune checkpoints when PD1 signaling is partially impaired. Beta cell specific stem-like memory T cells retain their functionality despite expressing multiple immune checkpoints and TIGIT is below PD1 in the hierarchy of immune checkpoints in autoimmune diabetes.

Indexed as

Diabetes Mellitus, Type 1AnimalsHumansImmune Checkpoint ProteinsLigandsMiceMice, Inbred NODReceptors, ImmunologicImmune Checkpoint ProteinsLigandsReceptors, ImmunologicT cell Ig and ITIM domain protein, mouseTIGIT protein, humanCD8+ T cellimmune checkpointNOD mouseTIGITtype 1 diabetes

Identifiers

PMID38533515
PMCPMC10964479
OpenAlexW4392704685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.